The FDA has approved SpringWorks Therapeutics’s mirdametinib (Gomekli) for adult and paediatric patients 2 years of age and older with neurofibromatosis type 1 (NF1) who have symptomatic ...

攻克癌症难题：免疫疗法联合 BRAF 和 MEK 抑制剂的新探索 在全球范围内 ... 此外，CRC 对免疫检查点抑制剂（Immune checkpoint inhibitors，ICIs）的响应普遍不佳，除了具有微卫星不稳定（Microsatellite instability，MSI）或错配修复（Mismatch repair，MMR）缺陷的转移性 CRC 患者 ...

Patients undergoing BRAF/MEK inhibitor therapy for melanoma more commonly experience VKH-like uveitis compared with other malignancy types.

This is a phase II open label study that will evaluate children ≥ 1 year of age and adults with neurofibromatosis type 1 (NF1) and plexiform neurofibromas treated with the MEK inhibitor, binimetinib.

This month, our discussion focuses on the clinical management of plexiform neurofibromas in the era of selumetinib, a MEK inhibitor medication that was approved by the FDA in 2020 for the treatment of ...

SWTX announced that the FDA had accepted its new drug application (“NDA”) seeking approval for the company’s investigational MEK inhibitor, mirdametinib, which is being developed for the ...

His presentation will focus on PAS-004, a next-generation macrocyclic MEK inhibitor being developed for neurofibromatosis type 1 and other cancer treatments. Lazarus will share interim data from ...

RAF dimer inhibitors, allosteric MEK inhibitors, ATP-competitive MEK inhibitors, and ERK inhibitors) in tumors expressing different RAS, RAF, or NF1 mutants. We have shown that tumors with HER2 ...

Trametinib, a mitogen-activated protein kinase (MEK) inhibitor, reduces mortality and morbidity in children with severe hypertrophic cardiomyopathy (HCM) caused by pathogenic variants in the RAS/MAPK ...

Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK ...

MIAMI, March 24, 2025 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a clinical-stage biotechnology company developing PAS-004, a next-generation ...